Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adynxx Inc.

www.adynxx.com

Latest From Adynxx Inc.

Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 


Pipeline Watch Approvals

Pipeline Watch: Phase III Starts With Plinabulin, Rova-T And Relugolix

Pipeline Watch is Scrip's weekly update on the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

VC Roundup: 2016 US Investment Ends On A Down Note, But Biopharma Has Second-Best Year

Venture capital investment fell $2.1bn to $7.79bn in 2016, but it was still the second-best year of VC funding for biopharma firms since 2006. Also, Venrock and Correlation closed new health care and technology funds and 10 companies raised $126.8m.

Financing StartUps and SMEs

Cubicin Becomes Blockbuster, As Cubist Passes on Adynxx Acquisition

The antibiotic developer said it will look to grow its portfolio of marketed products from three to four in 2014. Long-term it’s looking to do more acquisitions, perhaps with tax strategy in mind, but backed away from an option to acquire pain company Adynxx.

BioPharmaceutical Launches
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Adynxx Inc.
  • Senior Management
  • Rick Orr, CEO
    Julien Mamet, PhD, CSO
    Donald C Manning, MD, PhD, CMO
  • Contact Info
  • Adynxx Inc.
    Phone: (415) 512-7740
    100 Pine St.
    Ste. 500
    San Francisco, CA 94111
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register